Results 131 to 140 of about 7,834 (208)

Clinicopathological and functional evaluation of replication protein A in epithelial ovarian cancers: A target validation study. [PDF]

Transl Oncol
Algethami M, Sheha A, Singhania N, Alqahtani S, Shoqafi A, Tosun Ç, Spicer J, Toss MS, Alblihy A, Lashen A, Jeyapalan JN, Mongan NP, Rakha EA, Madhusudan S.   +13 more
europepmc   +1 more source

Differential sensitivity of MCPH1- and BRCA2-deficient cancer cells to PARP-1 inhibition. [PDF]

PLoS One
Chapman IG, Wu X, Veuger S, Jowsey PA.
europepmc   +1 more source

Talazoparib (Talzenna™)

Oncology Times, 2019
openaire   +2 more sources

Population Pharmacokinetics Analysis of Talazoparib and Enzalutamide Combination Therapy for Patients With Metastatic Castration-Resistant Prostate Cancer. [PDF]

J Clin Pharmacol
Hadigol M, Williams JH, Shi H, Yang DZ, Hoffman J, Wang DD.   +5 more
europepmc   +1 more source

Glioblastoma and PARP inhibitors: the importance of patient selection to maximize therapeutic benefits. A critical review. [PDF]

Front Oncol
Dima G, Di Nunno V, Aprile M, Gatto L, Tosoni A, Argento CM, Margotti M, Bartolini S, Franceschi E.   +8 more
europepmc   +1 more source

Talazoparib Formulation Bridging in Cancer Patients-Challenges and the Critical Role of Model-Informed Drug Development in Approval Despite Failed Bioequivalence. [PDF]

CPT Pharmacometrics Syst Pharmacol
Wang D, Guo CC, Gao X, Wang Y, Yu Y, Plotka A, Elmeliegy M, Shi H, Johnson S, DeAnnuntis L, Hoffman J.   +10 more
europepmc   +1 more source

Altered MDC1 Interactions and Dysfunctional DNA Repair in Lobular Breast Cancer Confers Sensitivity to PARP Inhibition. [PDF]

Cancer Res
Sottnik JL, Shackleford MT, Nesiba CS, Richer AL, Fleischmann Z, Swartz JM, Rowland CE, Musick M, Fu R, Myler LR, Opresko PL, Mehrotra S, Sokol ES, Hesselberth JR, Diamond JR, Sikora MJ.   +15 more
europepmc   +1 more source

Matching-adjusted indirect comparisons of PARP inhibitor combinations in metastatic castration-resistant prostate cancer across key populations. [PDF]

Oncologist
Castro E, Wang D, Paganelli S, Haltner A, Su N, Kirker M, Chang J, Samjoo IA.   +7 more
europepmc   +1 more source

Aurora kinase B phosphorylates ZBP1 to drive PANoptosis following treatment with PARP and ATR inhibitors combination. [PDF]

Nat Commun
Gong W, Liao Z, Xiong F, Wang L, Shi S, Luo M, Zhang Y, Xu Q, Wang Y, Wu Y, Zhu L, Kuang D, Labrie M, Mills GB, Ma D, Liu D, Zhao GN, Gao Q, Fang Y.   +18 more
europepmc   +1 more source

Targeting poly(ADP-ribose) polymerase in metastatic prostate cancer: current landscape and future directions. [PDF]

Curr Opin Oncol
Shi X, Rifai S, Meher Z, Hussain A.
europepmc   +1 more source